Gittelman M, Brown TM, Holm-Larsen T, Persson BE. Comparison of the impact of degarelix and leuprolide on the health-related quality of life of patients with prostate cancer: results of a 12-month phase III clinical trial. UroToday International Journal. 2011 Dec 1;4(6):Art. 81.
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol. 2010 Apr 1;24(4):489-96.
Novick D, Reed C, Gonzalez-Pinto A, Aguado J, Haro JM. Comparison of olanzapine and valproate over 12 months of treatment in the emblem study. J Psychopharmacol. 2010;24:A54.
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Antidepressant-induced sexual dysfunction in three European countries: prevalence and impact in a cross-sectional survey replication. J Psychopharmacol. 2007;21(Suppl):A39.
Fireman B, Mines D, Lee J, Hunkeler EM. The risk of suicide in patients treated with venlafaxine, fluoxetine, citalopram, or paroxetine at Kaiser Permanente in Northern California. Poster presented at the 2006 Summer Meeting of the British Association for Psychopharmacology; July 2006. Oxford, United Kingdom. [abstract] J Psychopharmacol. 2006 Sep; 20(5 Suppl):A58.
Tuells A, Arana A, Perez-Gutthann S, García-Rodríguez LA. El Proyecto BIFAP. Inv Clin Farm. 2003;0:25-6.